Expert Directory

Showing results 1 – 2 of 2

Armando Sardi, Universidad del Valle, Cali, Colombia

Medical Director, The Institute for Cancer Care at

Mercy Medical Center

Thyroid Cancer, Oncologist, Hyperthermic Intraperitoneal Chemotherapy, Cancer, medical director

Armando Sardi, M.D., is a respected and renowned Surgical Oncologist who has been honored as a Top Doc in Baltimore magazine multiple times. He serves as Medical Director of The Institute for Cancer Care at Mercy and as Chief of Division of Surgical Oncology at Mercy Medical Center in Downtown Baltimore, Maryland. Dr. Sardi is one of Maryland’s leading surgical oncologists who use Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat late-stage, complex cancers of the abdominal region. Dr. Sardi has been performing HIPEC procedures since 1994 and is considered to be among the best doctors using the technique. This advanced heated chemotherapy procedure is often a life-saving treatment option for patients who have exhausted more traditional treatment plans for stomach cancer. Patients have traveled to Mercy Medical Center from points up and down the East Coast to destinations across the U.S., to seek out Dr. Sardi for his cancer expertise in the HIPEC treatment.

Dr. Armando Sardi is a man whose professional focus is devoted to medical excellence, research and finding a cure for cancer. For his patients, Dr. Sardi’s personal concern and approach to their care are what helps them gain a positive outlook and confidence to face the challenges ahead. His cheerful smile and kind-hearted laugh immediately put patients at ease. And yet, his unyielding determination to give every patient the best possible chance to overcome their illness that ranks him among the best of the best. When other doctors have told patients there is no hope, Dr. Sardi tries even harder to beat the odds. Thanks to Dr. Sardi, the HIPEC procedure and other leading-edge treatment options, he has given patients so much more than hope. Patient after patient, year after year, have shared their stories at Mercy’s National Cancer Day Survivor Celebration and Mercy's annual Heat It to Beat It fundraising event. There are 3, 5, 10-year cancer survivors – each telling a heartwarming story of hope and survivorship. Dr. Sardi co-chair Mercy’s Cancer Committee and actively participates in The Tumor Board. These efforts allow cancer experts, specialists and key members of the healthcare team to discuss and collaborate on complex cancer cases to learn new and different ways to optimize resources, medical knowledge and treat patients so that long-term results will be improved.
Dr. Sardi also plays a key role in the Mercy National Cancer Survivor Day festivities. This joyous and spirited celebration is more than a reunion of cancer survivors, it is a day when Dr. Sardi and the Mercy family rejoice with their patients and loved ones. Together they have been through a long and challenging cancer journey and together they delight in all the possibilities ahead.
Dr. Armando Sardi, whose celebrated reputation has garnered local and international acclaim, has earned an international reputation for the advances he has made in the surgical oncology field and for his humanitarian efforts to care for the poor and underserved in third world countries. 
Dr. Sardi has been distinguished in Colombia, South America as one of the 100 Most Influential Expatriates – an honor received, in part, for the medical care he provides through the non-profit organization, Partners for Cancer Care and Prevention. This organization was the recipient of the Conquer Cancer Foundation's Inaugural International Innovation Grant.
Dr. Armando Sardi has been recognized for his research, leadership and compassionate bedside manner. Some of his awards include:

“Hispanic Hero Award for Excellence as a Medical/Social Entrepreneur”  Presented by USHYEE
“Gold Star Teamwork Award” Presented by The Sisters of Mercy in recognition of Gold Star performance
Honored by Fusionarte as one of “100 Colombianos” who represent the talent, creativity, and perseverance of Colombia. Bogota, Colombia December 2012
Named by Baltimore Magazine a "Top Doctor" in the Surgical Oncology specialty
Named by Castle Connelly Medical Ltd. a "Top Doctor" in Surgery
Dr. Sardi founded the annual HEAT IT TO BEAT IT benefit walk in Baltimore to raise awareness about HIPEC and cancer treatment.

Oncologist, Lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma), Blood Disorders, Blood Cancer, Leukemia, Hematology

Dr. Andrew M. Evens is a physician-scientist at the Rutgers Cancer Institute of New Jersey, where he is Associate Director for Clinical Services and Director of the Lymphoma Program. In addition, he is the Medical Director of the Oncology Service Line for the RWJBarnabas Health system. Dr. Evens completed a Hematology/Oncology fellowship at Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, where he was also Director of Translational Therapeutics. Prior to his Rutgers Cancer Institute appointment, Dr. Evens served as Chief of the Division of Hematology/Oncology at Tufts Medical Center and as Director of the Tufts Cancer Center in Boston, MA.

Dr. Evens is an associate editor for the British Journal of Haematology and serves on the editorial board for the Journal of Clinical Oncology. He is a core member of the Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee and has been a member of several clinical and scientific committees for the NIH, NCI, Cancer Therapy Evaluation Program (CTEP), Food and Drug Administration (FDA) and the ECOG/ACRIN group.  Dr. Evens is also an elected member of the Scientific Advisory Board for the Lymphoma Research Foundation (LRF) and he is involved in multiple national and international educational forums and events.

I completed a prior fellowship in hematology/oncology at Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center in Chicago, Illinois, where I also remained as a faculty member altogether for 10 years. Most recently, I served as the director of the Cancer Center at Tufts Medical Center in Boston, chief of their division of hematology/oncology, and Professor of Medicine at Tufts University School of Medicine.

My clinical expertise and research interests are fully dedicated to the field of lymphoma (i.e., Hodgkin lymphoma and non-Hodgkin lymphoma). Over the past 15+ years, I have been the principal investigator of more than 80 national and international cancer clinical trials that have included phase I, II, and III studies, many which have been “investigator-initiated” trials studying new and novel targeted agents for the treatment of lymphoid malignancies. In addition to my clinical research, I also manage a translational laboratory studying the biology of lymphoma and to discover new and novel treatments for patients. Collectively, my research has been continuously funded by the National Institutes of Health (NIH) and the NCI since 2005. This has resulted in 200+ research abstracts at national and international cancer research symposiums, 150+ manuscripts in peer-reviewed publications, and 20+ book chapters all with an emphasis on the biology, prognosis, and treatment of lymphoma.

My involvement in the advancement of cancer research has also included leadership roles in academic journals, symposiums, cancer advocacy groups, and international committees. I was an associate editor for the British Journal of Haematology and on the editorial board for the Journal of Clinical Oncology and am the inaugural editor in chief for the open access journal, eJHaem. I am a core member of the Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee and I have been a member of several additional clinical and scientific committees for the NIH, NCI, Cancer Therapy Evaluation Program (CTEP), Food and Drug Administration (FDA) and the ECOG/ACRIN group. Furthermore, I am Co-Chair of the Lymphoma Committee for the ECOG-ACRIN cancer research group and am honored to be an elected member of the North American Scientific Advisory Board for the Lymphoma Research Foundation (LRF) and a member of the Board of Trustees for the Leukemia & Lymphoma Society (LLS) New Jersey Chapter. Finally, I am involved and help lead a multitude of regional, national, and international educational forums and events.

Positions:
Associate Director for Clinical Services at Rutgers Cancer Institute of New Jersey
Medical Director of the Oncology Service Line, RWJBarnabas Health
Director, Lymphoma Program, Division of Blood Disorders

Clinical Expertise:
Hodgkin lymphoma, non-Hodgkin lymphoma (all types), chronic lymphocytic leukemia, and autologous hematopoietic stem cell (or bone marrow) transplantation.

Research Interests:
Lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma)
Chronic lymphocytic leukemia and other lymphoid malignancies
Clinical trials
Translational studies, including lymphoma biology and drug discovery
Systems biology and biomarker analyses
Lymphoma epidemiology
Health Outcomes, including Pharmacovigilance and Decision Making

I am thrilled to be a member of the Rutgers Cancer Institute of New Jersey (CINJ) as the Associate Director for Clinical Services, Medical Director of the Oncology Service Line for RWJBarnabas Health, and Director of the Lymphoma Program. Rutgers Cancer Institute is unique in that it is New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center. Our mission is to deliver integrated cancer care across the health system with access to academic expertise and innovative cancer therapies not available elsewhere in the state.

Showing results 1 – 2 of 2

close
0.82289